Actively Recruiting
Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
Led by Shanghai Zhongshan Hospital · Updated on 2025-03-26
240
Participants Needed
1
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.
CONDITIONS
Official Title
Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a first diagnosis of HCC
- Patients with HCC who are to undergo surgical treatment, with or without neoadjuvant therapy
- Ability to obtain tissue sample for ctDNA analysis and detectable baseline ctDNA level
You will not qualify if you...
- Patients with secondary liver cancer, or intrahepatic cholangiocarcinoma
- Any other concurrent malignancy
- History of organ transplant or hepatic encephalopathy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital Fudan University
Shanghai, China, 200032
Actively Recruiting
Research Team
H
Huichuan Sun
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here